BRIEF-Diamedica Therapeutics Announces 75% Enrollment Milestone In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial

DiaMedica Therapeutics

DiaMedica Therapeutics

DMAC

0.00

- DiaMedica Therapeutics Inc DMAC.O:

  • DIAMEDICA THERAPEUTICS ANNOUNCES 75% ENROLLMENT MILESTONE IN REMEDY2 PHASE 2/3 ACUTE ISCHEMIC STROKE TRIAL

Source text: ID:nBw9gmQNQa

Further company coverage: DMAC.O